Amunix links with Biogen Idec for next generation long-lasting blood factor products

14 April 2011

Privately-held biotech firm Amunix has entered into an exclusive worldwide research collaboration and option agreement with fellow USA-based Biogen Idec (Nasdaq: BIIB) to research and develop novel, fully-recombinant blood factors (Factors IX, VIII and VIIa) with improved therapeutic properties.

The partnership will combine California-headquartered Amunix' protein half-life engineering expertise, based on its proprietary XTEN technology, and Biogen’s broad range of capabilities in research, manufacturing and clinical development of recombinant blood factors for hemophilia.

Commenting on the deal, Glenn Pierce, senior vice president of Biogen Idec Hemophilia, said: "We have a long-term commitment to hemophilia. In addition to advancing our current late-stage long-lasting Factor IX and Factor VIII programs, we continue to invest in innovations like XTEN, which have the potential to bring further-improved treatment options to the hemophilia community."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK